india market reflection report feb 2015

0

Market Reflection Report February 2015

1

IPM overview


TSA IPM Trends SSA IPM Trends

IPM was valued at Rs. 89,244 crs and the retail sector was valued at Rs. 75,551 crs, both with a growth of 20% in

Feb‘15 over the same month last year; CAGR growth of 11% during the period 2012-15

Multiple factors like prevalence of swine flu-H1N1, high growth in anti-infectives, respiratory and pain market with

expansion of big brands, has resulted in overall robust IPM growth of 20% for the month

Indian companies continue to drive growth in the market with a growth of 22% in Feb ‘15

Cardiac and Gastro Intestinal, with respective market share of 12% and 10%, constitutes the 2nd and 3rd largest therapies

Mo

nth

Gro

wth

%

Value Rs. crs

Growth SPLY

89,244

79,823

72,655

65,375

7,5426,3115,8355,343

+20%

+12%

2013 2012 2015 2014

75,551

67,213

61,070

55,025

6,3825,3214,9034,479

2012

+20%

+12%

2015 2014 2013

Month MAT

20

15

10

5

0

Jun May Apr Mar Feb Jan Dec Nov Oct Sep Aug Jul

20

15

10

5

0

Jan Dec Nov Oct Sep Aug Jul Jun May Apr Mar Feb

2013

2015

2014

2

Top 150 companies snapshot


• The top 10 companies constituted 40% market share of IPM on MAT and month basis

• Similarly, the top 150 companies constituted 97% market share of IPM on MAT and month basis

• For the top companies, growth was driven by top 300 brands which grew by 11% for top # 1-10 companies

Source: IMS Health TSA, Feb ‘15

IPM value – Rs.7,542 crs (19.5% Growth)

Month Feb ‘15 IPM value – Rs.89,244 crs (11.8% Growth)

MAT Feb ‘15

253

507

503

415

911

Value (Rs. Crs)

Rank #101 - 150

Rank #61 - 100

Rank #41 - 60

Rank #31 - 40

Rank #21 - 30

Rank #11 - 20 1,721

Rank #1 - 10 3,020

3

7

7

6

12

23

40

% MS

11

20

25

17

22

23

17

% Gwth Value (Rs. Crs)

3,118

6,103

5,990

4,988

10,638

20,042

35,861

4

7

7

6

12

22

40

% MS

8

14

18

11

10

12

11

% Gwth

3

Top companies #1-10


TSA: Macleods, Mankind and Cipla registered remarkable growth both on MAT and month basis.

SSA: Macleods registered the highest growth both on MAT and month basis followed by Mankind

Source: IMS Health TSA & SSA, Feb ‘15

256

259

261

268

367

410

469

Value

(Rs. Crs)

Pfizer 236

GlaxoSmithKline 241

Alkem 253

Macleods Pharma

Ranbaxy

Zydus Cadila

Mankind

Sun

Cipla

Abbott

18

8

20

34

10

9

27

17

21

13

% Gwth

3.1

3.2

3.4

3.4

3.4

3.5

3.6

4.9

5.4

6.2

% MS

191

199

221

221

225

226

239

306

324

403

Value

(Rs. Crs)

Pfizer

GlaxoSmithKline

Alkem

Zydus Cadila

Ranbaxy

Macleods Pharma

Mankind

Sun

Cipla

Abbott

17

10

22

10

9

36

28

20

21

12

% Gwth

3.0

3.1

3.5

3.5

3.5

3.5

3.8

4.8

5.1

6.3

% MS

Mo

nth

Value

(Rs. Crs)

Pfizer 2,723

Macleods Pharma 2,875

GlaxoSmithKline 3,062

Alkem 3,071

Mankind 3,118

Zydus Cadila 3,163

Ranbaxy 3,233

Sun 4,242

Cipla 4,691

Abbott 5,684

9

23

4

11

18

3

6

13

20

7

% Gwth

3.1

3.2

3.4

3.4

3.5

3.5

3.6

4.8

5.3

6.4

% MS

2,501

Macleods Pharma 2,505

Zydus Cadila 2,651

Alkem 2,677

Mankind 2,779

Ranbaxy 2,826

Sun 3,515

Cipla 3,722

Abbott 4,930

Value

(Rs. Crs)

Pfizer 2,203

Glaxosmithkline

8

7

25

4

12

19

6

15

16

8

% Gwth

2.9

3.3

3.3

3.5

3.5

3.7

3.7

4.7

4.9

6.5

% MS

MA

T

SS

A T

SA

4

Top companies #11-20


• TSA – Intas continued to register the highest growth of 39% on month basis and 20% on MAT basis among the top

11-20 companies

• SSA – Additional to Intas, few companies have registered significant growth on month basis such as Aristo Pharma,

Alembic and Dr Reddys Labs; while Glenmark Pharma posted significant growth on MAT basis Source: IMS Health TSA & SSA, Feb ‘15

168

168

173

174

186

212

213

Value

(Rs. Crs)

Alembic 132

U S V 147

Glenmark Pharma 154

Aristo Pharma

Dr Reddys Labs

Sanofi

Emcure

Torrent Pharma

Intas Pharma

Lupin Limited

28

15

26

27

24

21

14

26

39

21

% Gwth

1.8

2.0

2.0

2.2

2.2

2.3

2.3

2.5

2.8

2.8

% MS

119

127

132

134

143

147

150

163

180

182

Value

(Rs. Crs)

Alembic

Sanofi

U S V

Glenmark Pharma

Dr Reddys Labs

Emcure

Aristo Pharma

Torrent Pharma

Lupin Limited

Intas Pharma

28

17

15

25

28

15

29

27

21

39

% Gwth

1.9

2.0

2.1

2.1

2.2

2.3

2.3

2.6

2.8

2.8

% MS

Value

(Rs. Crs)

Micro Labs 1,502

U S V 1,733

Glenmark Pharma 1,756

Dr Reddys Labs 1,908

Aristo Pharma 1,980

Sanofi 2,037

Emcure 2,113

Torrent Pharma 2,134

Intas Pharma 2,330

Lupin Limited 2,549

6

9

19

12

14

3

13

9

20

15

% Gwth

1.7

1.9

2.0

2.1

2.2

2.3

2.4

2.4

2.6

2.9

% MS

Value

(Rs. Crs)

Alembic 1,331

Glenmark Pharma 1,531

Sanofi 1,533

U S V 1,563

Dr Reddys Labs 1,615

Aristo Pharma 1,762

Emcure 1,765

Torrent Pharma 1,870

Intas Pharma 1,993

Lupin Limited 2,145

13

19

12

10

15

14

14

10

19

16

% Gwth

1.8

2.0

2.0

2.1

2.1

2.3

2.3

2.5

2.6

2.8

% MS

SS

A T

SA

Mo

nth

M

AT

5

Top companies #21-30


• TSA – IPCA continued to register significant growth of 39% during the month followed by Wockhardt and Cadila Pharma

• SSA – Apart from IPCA, Cadila registered significant growth of 35% during the month followed by Wockhardt at 25%

Source: IMS Health TSA & SSA, Feb ‘15

74

82

93

108

109

122

126

59

61

72

Value

(Rs. Crs)

Franco Indian

Merck Limited

Msd Pharmaceutical

Cadila Pharma

Unichem

FDC

Novartis Intl.

Ipca Labs

Wockhardt Ltd

Micro Labs

14

9

8

13

6

36

23

39

36

17

% Gwth

0.8

0.8

1.0

1.0

1.1

1.2

1.4

1.4

1.6

1.7

% MS

54

55

57

62

74

86

95

96

101

105

Value

(Rs. Crs)

Merck Limited

Franco Indian

Msd Pharmaceutical

Cadila Pharma

Unichem

Fdc

Novartis Intl.

Ipca Labs

Wockhardt Ltd

Micro Labs

15

8

7

35

15

24

12

41

25

16

% Gwth

0.8

0.9

0.9

1.0

1.2

1.4

1.5

1.5

1.6

1.7

% MS

726

772

827

952

998

Value

(Rs. Crs)

Franco Indian

Merck Limited

Cadila Pharma

Msd Pharmaceutical

Unichem

FDC 1,048

Wockhardt Ltd 1,241

Ipca Labs 1,276

Novartis Intl. 1,328

Alembic 1,469

11

10

12

9

8

7

11

19

3

13

% Gwth

0.8

0.9

0.9

1.1

1.1

1.2

1.4

1.4

1.5

1.7

% MS

681

684

705

753

905

971

Value

(Rs. Crs)

Merck Limited

Franco Indian

Cadila Pharma

Msd Pharmaceutical

Unichem

Fdc

Wockhardt Ltd 1,071

Ipca Labs 1,114

Novartis Intl. 1,156

Micro Labs 1,270

10

12

12

10

8

8

7

20

3

8

% Gwth

0.9

0.9

0.9

1.0

1.2

1.3

1.4

1.5

1.5

1.7

% MS

SS

A T

SA

Mo

nth

M

AT

6

Highlights


TSA

Movers & Shakers TSA: Companies

In the month of Feb’15 (in comparison to

Jan’15), among the top 25 companies

Macleods Pharma has gained 3 ranks and

moved to 7th position.

Mankind, Aristo Pharma and Wockhardt have

gained 2 ranks each and moved to 4th, 17th and

22nd position, respectively.

Alkem, Alembic and FDC have gained 1 rank

each and moved to 8th, 20th and 25th position,

respectively.

As per Feb’15 MAT (in comparison to Jan’15)

among the top 25 companies

Abbott has maintained its top position with

market share of 6.37%

Alkem has gained 1 rank and moved to 7th

position.

SSA

Movers & Shakers SSA: Companies

In the month of Feb-15 (in comparison to Jan-

15 month), among the TOP 25 companies


market share of 6.31%.

Aristo Pharma has gained 4 ranks and occupied

14th position.

Macleods Pharma has gained 3 ranks and

occupied 5th position.

Wockhardt has gained 2 ranks and occupied

22nd position.

Intas and FDC have gained 1 rank each and

occupied 11th and 25th position, respectively.

As per Feb-15 MAT (in comparison to Jan-15

MAT), among the TOP 25 companies


market share of 6.53%.

Macleods Pharma has gained 1 rank and

occupied 8th position.

7

NLEM/Non-NLEM


Valu

e

Vo

lum

e

NLEM impacted drugs constituted 13% of IPM in value terms with a growth of 11.5% in Feb ‘15 over same period

last year (SPLY)

The share of the non-NLEM drugs was 87% of IPM in value terms and 78% in volume terms for the month of Feb’15

The volume of NLEM drugs witnessed growth of 8% in Feb ’15 over the same period last year.


SPLY Previous month

Feb '14 Feb '15 Value Growth

(%)

Jan '14 Feb '15 Value Growth (%)

Rs. (crs) Rs. (crs) Rs. (crs) Rs. (crs)

NLEM 909.1 1014.0 11.5 975.2 1014.0 4.0

Non-NLEM 5402.3 6528.3 20.8 6446.7 6528.3 1.3

IPM 6311.5 7542.3 19.5 7421.9 7542.3 1.6

SPLY Previous month

Feb '14 Feb '15 Volume Growth

(% )

Jan '14 Feb '15 Volume Growth

(%) Units (‘000) Units (‘000) Units (‘000) Units (‘000)

NLEM 356471 384836 8.0 367813 384836 4.6

Non-NLEM 1180693 1343376 13.8 1296134 1343376 3.6

IPM 1537164 1728211 12.4 1663947 1728211 3.9

8

Indian /MNC trends


• Indian companies continue to capture the larger share of IPM at 74% during the month with a significant growth of

22% over Feb’14

• With 3 MNCs represented in the top 10 companies, the share of MNCs constituted 26% of IPM


0

5

10

15

20

25

% Gwth over same month last year

MNC

Indian

IPM

Feb ’15 Jan ’15 Dec ’14 Nov ’14 Oct ’14 Sep ’14 Aug ’14 Jul ’14 Jun ’14 May ’14 Apr ’14 Mar ’14

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

Value (Rs. Crs)

MNC

Indian

IPM


Mo

nth

Gro

wth

V

alu

e

9

Acute/Chronic trends


Acute therapies continue to dominate the market accounting for 70% of the market during the month

Chronic therapies registered growth of 18%, while acute therapies attained significant growth of 20% over Feb’14

Cough preparation was the highest selling therapeutic subgroup in value terms with significant growth of 35% on month

basis Source: IMS Health TSA, Feb ‘15

5

10

15

20

25


9584109116

176

Amoxy. & Clav. Solids Food Supplements Glim+Metformin DPP4 inhibitors & Comb Cough Preps Ethical

34.93 27.23 20.09 -5.38 27.58

9

18

23

Franco Indian

Wockhardt Ltd

Glenmark Pharma

18

26

28

U S V

Novartis Intl.

MSD Pharma

10

10

23

Lupin Limited

Sun

U S V

12

13

14

Nutricia Internat

Abbott

Apex

15

15

17

Mankind

Alkem

GlaxoSmithKline

To

p 5

TC

4s

T

op

3 C

os. in

TC

4

Growth (%)

Value (Rs.

Crs)

Value (Rs. Crs)

Gro

wth

(%

)

Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs) Value (Rs. Crs)

Chronic IPM Acute

10

Top 40 brands


Alburel (Reliance Life Sciences) registered outstanding growth of 118% during the month

Being a new launch, Biovac V (Wockhardt) has registered astounding growth and attained its position in top 40 brands

Magnex (Pfizer), Prevenar-13 (Pfizer), Panderm+ (Macleods), Thyronorm (Abbott) and Electral (FDC) posted impressive

growth greater than 50% in Feb ’15 over the same month last year

22

22

22

23

30

30

38

19

20

22

Value

(Rs. Crs)

Phensedyl Cough

Monocef

Prevenar-13

Clavam

Panderm+

Thyronorm

Glycomet-GP

Corex

Augmentin

Mixtard

-9

29

70

24

60

56

22

16

35

14

% Gwth % MS

0.26

0.27

0.29

0.29

0.30

0.30

0.31

0.40

0.40

0.50

15

15

15

15

15

16

16

16

16

15

Value

(Rs. Crs)

Zifi

Becosules

Azithral

Budecort

Shelcal

Alburel

Moxikind-CV

Biovac V

Foracort

Liv-52

35

16

38

41

34

30

23

8

% Gwth

999

118

% MS

0.20

0.20

0.20

0.20

0.20

0.20

0.21

0.21

0.22

0.22

16

17

17

18

18

18

18

18

18

19

Volini

Novomix

Voveran

Value

(Rs. Crs)

Electral

Spasmo-Proxyvon +

Lantus

Dexorange

Galvus Met

Betadine

Janumet

56

3

20

7

16

12

29

1

23

30

% Gwth % MS

0.22

0.23

0.23

0.23

0.23

0.23

0.24

0.24

0.24

0.25

13

13

13

13

13

14

14

14

14

14

Value

(Rs. Crs)

Synflorix

Seroflo

Zinetac

Magnex

Zincovit

Duphaston

Taxim-o

Aciloc

Calpol

Pan

50

14

5

81

7

17

15

28

35

13

% Gwth

0.17

% MS

0.17

0.18

0.18

0.18

0.18

0.18

0.18

0.18

0.19

To

p 1

-10

To

p 1

1-2

0

To

p 2

1-3

0

To

p 3

1-4

0


11

Star Brands of the month


TSA

Movers & Shakers TSA: Products

Among the Top 25 products as per Feb’15 month (in comparison to Jan’15 month)

Mixtard (Abbott) is the No 1 brand.

Alburel (Reliance Life Sciences) has gained 29 ranks to occupy 25th position.

Monocef (Aristo Pharmaceuticals) has gained 12 ranks to occupy 9th position.

Dexorange (Franco-Indian) and Moxikind CV (Mankind) has gained 9 ranks to occupy 17th and 24th position,

respectively.

Panderm+ (Macleods) and Clavam (Alkem) has gained 6 ranks to occupy 6th and 7th position, respectively.

Thyronorm (Abbott), Betadine (Win Medicare), Electral (FDC) and Liv-52 (Himalaya) have gained 2 ranks each to

occupy 5th ,15th, 20th and 21st position, respectively.

Augmentin (GSK) and Volini (Ranbaxy) have gained 1 rank each to occupy 2nd and 13th position, respectively

Among the Top 25 products as per Feb’15 MAT (in comparison to Jan’15 MAT)

Mixtard (Abbott) is the No 1 brand.

Panderm + (Macleods) has gained 3 ranks to occupy 21st position.

Prevenar-13 (Pfizer) has gained 2 ranks to occupy 9th position.

Volini (Ranbaxy), Dexorange (Franco-Indian), Thyronorm (Abbott), Novomix (Abbott), Janumet (MSD) and Shelcal

(Torrent Pharma) have gained 1 rank each to occupy 6th, 7th, 8th,14th, 17th and 24th position, respectively.

12

Vaccines 164

Others 235

Gynaec. 416

Neuro / CNS 454

Derma 462

Vitamins / Minerals / Nutrients 527

Anti Diabetic 583

Pain / Analgesics 594

Respiratory 695

Gastro Intestinal 771

Cardiac 873

Anti-infectives 1,111

IPM 7,542

6

6

6

2

3

7

8

8

9

10

12

15

100

15

16

42

23

14

19

21

20

24

19

16

23

20

1

1

-4

-3

-5

1

-5

3

8

2

-5

15

2

Gwth % (SPLY) Gwth% (Prev. Mth)

Therapy trends

• Vaccines recorded significant value growth of 42% as of MAT Feb ’15

• Anti-infectives constitute the largest market share of 15%, with significant growth both on month and MAT basis



Value (Rs Crs) MS %

13

Top Therapy Trends



29

30

33

33

42

44

48

54

57

95

Value

(Rs. Crs)

Amikacin

Cefuroxime Oral Solids

Meropenem

Piperacillin+Tazobactam

Cefpodoxime Solids

Azithromycin Oral Solids

Amoxy. & Clav. Liquids

Cefixime Oral Sol.

Ceftriaxone Injectabls

Amoxy. & Clav. Solids

28

16

7

22

30

39

16

30

28

27

% Gwth (SPLY)

18

24

29

29

31

32

33

40

43

66

Value

(Rs. Crs)

Losartan+ Hydrochlorthiaz

Amlodipine+Telmisartan

Amlodipine

Enoxaparin

Telmisartan + HCT

Atenolol+Amlodipine

Metoprolol

Telmisartan

Rosuvastatin

Atorvastatin

5

26

9

6

11

15

12

22

23

14

% Gwth (SPLY)

An

ti-I

nfe

cti

ve

21

22

23

24

27

29

38

39

43

47

Value

(Rs. Crs)

Digest. Inc. Enzyme Liqui

Rabeprazole

Omepraz.+ Domperid.

Antacid+Antiflatu.Liq

Others

Oral Electrolytes

Pantoprazole Solids

Ranitidine Oral Solids

Rabepra.+ Domperid.

Pantopr.+ Domperid.

26

13

14

20

23

47

15

14

24

25

% Gwth (SPLY)

14

15

18

21

30

31

40

42

67

176

Value

(Rs. Crs)

Levocetirizine

Salbutamol+Ipratropium

Budesonide

Salmeterol+Fluticasone

Cold Prep. Solids

Formoteral+Budesonide

Levocetiriz.+Montelu Sold

Cold Prep. Liquids

Codeine And Comb.

Cough Prep. Ethicals

21

28

42

17

24

23

26

23

8

35

% Gwth (SPLY)

Card

iac

GI

Resp

irato

ry

• Oral Electrolytes, Budesonide, Amikacin and Cough Prep. Ethicals registered significant growth greater than 30%

over the same period last year

14

Glossary


Abbreviation Description/Definition

IPM Indian Pharmaceutical Market

MAT Moving Annual Total

CAGR Compound Annual Growth Rate

TSA Total Sales Audit

SSA Secondary Sales Audit

Gwth Growth

MS Market Share

Rs Rupees

NLEM National List of Essential Medicines

SPLY Same Period Late Year

MNC Multi-National Company

DPP Dipeptidyl Peptidase 4

TC Therapeutic Category

Crore / crs 10 million

15

About IMS Health World’s leading provider of healthcare consulting, technology, and informatics

Founded in 1954

Operates in over 100 countries; employs 10,000+ people world wide

Data from 100,000 suppliers and insights of more than 40 billion healthcare transactions

1200+ experts resources, 3000+ service resources and 5000+ clients

Operational in India for more than 11 years, with over 2000 employees with of f ices in Gurgaon, Mumbai, Delhi & Bangalore

PUBLIC HEALTH

Policy reforms and advocacy Enabling evidence based public health

decisions

Health infrastructure development Health resources planning and

allocation Monitoring & evaluation Designing and implementation support

Strengthening health care supply chain

Enabling Technology Solutions

Product & Portfolio strategy Entry & Growth Strategy Brand and Commercial Strategy

Pricing and market access Launch and commercial Excellence

Performance management Transaction Advisory Services and

Due Diligence

Drug sales database (global and local) Census - Physicians, Chemists,

Hospitals, Doctor , etc

PHARMA & ALLIED HEALTH

Network expansion and management Doctor selection Pharma & Provider engagement

strategy Disease management

Claims database Claims analytics – benchmarks and

costs

Patient level information Health technology assessment

PAYERS PROVIDERS

Provider databases Hospital performance transformation

programs

Performance benchmarking Expansion & Growth strategy

Feasibility analysis and business plan development

Brownfield hospital acquisition

Financial modeling, funding modalities and transaction advisory

BI Solutions for hospitals

OUR SERVICE OFFERINGS

95 process patents worldwide in life sciences processes

Ranked 2nd Life Science

Technology Vendors for 2013 (IT Services) by IDC

World’s most admired companies FORTUNE Magazine

2008 and 2010

PHARMA AND LIFE-SCIENCES

16

Disclaimer

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats,

and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the

completeness or accuracy of such third party sources or data.

As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks

and uncertainties, and are not to be considered guarantees of any particular outcome.

It should neither be regarded as comprehensive nor sufficient for making decisions, nor should it be used in place of professional advice. IMS Health

accepts no responsibility for any loss arising from any action taken or not taken by anyone using this material.

All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by

any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of

IMS HEALTH.

©2015 IMS Health Incorporated and its affiliates. All rights reserved. Trademarks are registered in the United States and in various other countries.

india market reflection report feb 2015

Healthcare